We recently reported a 59 year old female, designated WHIM-09, who was born with the rare immunodeficiency disease WHIM syndrome but underwent spontaneous phenotypic reversion as an adult. The causative WHIM mutation CXCR4 (R334X) was absent in her myeloid and erythroid lineage, but present in her lymphoid lineage and in epithelial cells, defining her as a somatic genetic mosaic. Genomic and hematologic analysis revealed chromothripsis (chromosome shattering) on one copy of chromosome 2, which deleted 164 genes including CXCR4 (R334X) in a single haematopoietic stem cell (HSC) (Fig. 1). Experiments in mice indicated that deleting one copy of Cxcr4 is sufficient to confer a selective advantage for engraftment of transplanted HSCs, suggesting a mechanism for clinical cure in WHIM-09. Genome editing may allow autologous transplantation of HSCs lacking one copy of CXCR4 without bone marrow conditioning as a general cure strategy in WHIM syndrome, safely recapitulating the outcome in patient WHIM-09. Figure 1.Chromothripsis (chromosomal shattering) resulted in clinical cure of a patient with a rare immunodeficiency (WHIM syndrome) by deleting the mutant copy of CXCR4.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588533PMC
http://dx.doi.org/10.1080/21675511.2015.1073430DOI Listing

Publication Analysis

Top Keywords

copy cxcr4
12
bone marrow
8
rare immunodeficiency
8
cxcr4 r334x
8
clinical cure
8
cxcr4
5
chromothriptic cure
4
syndrome
4
cure syndrome
4
syndrome implications
4

Similar Publications

Introduction: Bladder cancer was recognized as one of the most common malignant tumors in the urinary system, and treatment options remained largely limited to conventional surgery, radiotherapy, and chemotherapy, which limited patient benefits.

Methods: Researchers constructed an RNA transcriptome map of bladder cancer by integrating single-cell RNA sequencing and clinical data, identifying potential molecular targets for diagnosis and treatment. We also verified the antitumor activity of the target through in vitro experiment.

View Article and Find Full Text PDF

Impact of Hashimoto's thyroiditis on the tumor microenvironment in papillary thyroid cancer: insights from single-cell analysis.

Front Endocrinol (Lausanne)

October 2024

Department of Pharmacogenomics, College of Bioinformatics and Science Technology, Harbin Medical University, Harbin, China.

Article Synopsis
  • This study analyzes the effects of Hashimoto's thyroiditis (HT) on the microenvironment of papillary thyroid cancer (PTC) using extensive single-cell data from 11 patients.
  • It highlights specific cell populations related to HT that create a thyroid-stimulating hormone (TSH)-suppressive environment and promote immune interactions, crucial for personalized medicine approaches.
  • The research also introduces a new method for analyzing RNA-seq data, enhancing the understanding of the relationship between autoimmunity and cancer, and potentially revealing new therapeutic targets for PTC.
View Article and Find Full Text PDF

Recent studies highlighted genetic aberrations associated with prognosis in Mantle Cell lymphoma (MCL), yet comprehensive testing is not implemented in clinical routine. We conducted a comprehensive genomic characterization of 180 patients from the European MCL network trials by targeted sequencing of peripheral blood DNA using the EuroClonality(EC)-NDC assay. The IGH::CCND1 fusion was identified in 94% of patients, clonal IGH-V-(D)-J rearrangements in all, and 79% had ≥1 somatic gene mutation.

View Article and Find Full Text PDF

Introduction: Hepatocellular carcinoma (HCC) is characterized by the complex pathogenesis, limited therapeutic methods, and poor prognosis. Endoplasmic reticulum stress (ERS) plays an important role in the development of HCC, therefore, we still need further study of molecular mechanism of HCC and ERS for early diagnosis and promising treatment targets.

Method: The GEO datasets (GSE25097, GSE62232, and GSE65372) were integrated to identify differentially expressed genes related to HCC (ERSRGs).

View Article and Find Full Text PDF

Banxia-Shengjiang drug pair inhibits gastric cancer development and progression by improving body immunity.

Medicine (Baltimore)

March 2024

Key Laboratory of Hui Ethnic Medicine Modernization of Ministry of Education, Ningxia Medical University, Yinchuan, Ningxia, China.

To investigate the mechanism of action of Banxia-Shengjiang drug pair on the inhibition of gastric cancer (GC) using network pharmacology and bioinformatics techniques. The action targets of the Banxia (Pinellia ternata (Thunb.) Makino) -Shengjiang (Zingiber officinale Roscoe) drug pair obtained from the TCMSP database were intersected with differentially expressed genes (DEGs) and GC-related genes, and the intersected genes were analyzed for pathway enrichment to identify the signaling pathways and core target genes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!